Om P. Ganda

7.5k total citations · 1 hit paper
83 papers, 3.7k citations indexed

About

Om P. Ganda is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Genetics. According to data from OpenAlex, Om P. Ganda has authored 83 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Endocrinology, Diabetes and Metabolism, 40 papers in Surgery and 16 papers in Genetics. Recurrent topics in Om P. Ganda's work include Diabetes Management and Research (21 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (21 papers) and Lipoproteins and Cardiovascular Health (20 papers). Om P. Ganda is often cited by papers focused on Diabetes Management and Research (21 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (21 papers) and Lipoproteins and Cardiovascular Health (20 papers). Om P. Ganda collaborates with scholars based in United States, Canada and India. Om P. Ganda's co-authors include J. Stuart Soeldner, George S. Eisenbarth, S. Srikanta, Anoop Misra, Neil B. Ruderman, Charles F. Arkin, Ray E. Gleason, Aldo A. Rossini, Helena W. Rodbard and Mark D. Shepherd and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Investigation.

In The Last Decade

Om P. Ganda

78 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis

2012 407 citations Om P. Ganda et al. Endocrine Practice profile →

Peers

Countries citing papers authored by Om P. Ganda

Since Specialization

Citations

This map shows the geographic impact of Om P. Ganda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Om P. Ganda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Om P. Ganda more than expected).

Fields of papers citing papers by Om P. Ganda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Om P. Ganda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Om P. Ganda. The network helps show where Om P. Ganda may publish in the future.

Co-authorship network of co-authors of Om P. Ganda

This figure shows the co-authorship network connecting the top 25 collaborators of Om P. Ganda. A scholar is included among the top collaborators of Om P. Ganda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Om P. Ganda. Om P. Ganda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adherence to Lipid‐Lowering Therapies and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta‐Analysis 2025 ·Journal of the American Heart Association ·Laney K. Jones, Cara East, Om P. Ganda, Michael R. Gionfriddo	0
2	Comparison of product label vs real-world safety data from branded icosapent ethyl users: A select analysis utilizing MarketScan data 2025 ·Journal of clinical lipidology ·John Nelson, Richard A. Hansen, Handrean Soran, (unknown), Om P. Ganda, David Abrahamson, Kaveh Hosseini, Hakima Hannachi, Sephy Philip	0
3	Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease 2023 ·Current Opinion in Lipidology ·Om P. Ganda	20
4	Unusual Responses to PCSK9 Inhibitors in a Real-world Clinical Cohort 2020 ·SHILAP Revista de lepidopterología ·Bruce A. Warden, (unknown), Carlota Oleaga, Om P. Ganda, P. Barton Duell, Jonathan Q. Purnell, Michael D. Shapiro, (unknown)	1
5	When to lower triglycerides? 2020 ·Current Opinion in Lipidology ·Om P. Ganda	6
6	Diabetes in ageing: pathways for developing the evidence base for clinical guidance 2020 ·The Lancet Diabetes & Endocrinology ·Medha Munshi, Graydon S. Meneilly, Leocadio Rodríguez‐Mañas, Kelly L. Close, Paul R. Conlin, Tali Cukierman‐Yaffe, Angus Forbes, Om P. Ganda, C. Ronald Kahn, Elbert S. Huang, Lori M. Laffel, Christine G. Lee, Sei Lee, David M. Nathan, Naushira Pandya, Richard E. Pratley, Robert A. Gabbay, Alan J. Sinclair	54
7	Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol 2020 ·SHILAP Revista de lepidopterología ·Bruce A. Warden, Joshua Miles, Carlota Oleaga, Om P. Ganda, P. Barton Duell, Jonathan Q. Purnell, Michael D. Shapiro, Sergio Fazio	14
8	Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management 2018 ·Journal of the American College of Cardiology ·Om P. Ganda, Deepak L. Bhatt, R. Preston Mason, Michael Miller, William E. Boden	138
9	mHealth Intervention to Improve Diabetes Risk Behaviors in India: A Prospective, Parallel Group Cohort Study 2016 ·Journal of Medical Internet Research ·Angela Fidler Pfammatter, Bonnie Spring, (unknown), (unknown), (unknown), (unknown), Monika Arora, Harish Ranjani, Om P. Ganda, Donald Hedeker, S. Sethu K. Reddy, (unknown)	64
10	Homozygous lecithin:cholesterol acyltransferase (LCAT) deficiency due to a new loss of function mutation and review of the literature 2011 ·Journal of clinical lipidology ·Bijan Roshan, Om P. Ganda, Ranil DeSilva, (unknown), (unknown), Sarah Haessler, Eliana Polisecki, Bela F. Asztalos, Ernst J. Schaefer	13
11	The Role of Bile Acid Sequestrants in the Management of Type 2 Diabetes Mellitus 2010 ·Metabolic Syndrome and Related Disorders ·Om P. Ganda	4
12	Salt Sensitivity, Insulin Resistance and Public Health in India 2010 ·Endocrine Practice ·Om P. Ganda, Vivian Fonseca	8
13	Refining Lipoprotein Assessment in Diabetes: Apolipoprotein B Makes Sense 2009 ·Endocrine Practice ·Om P. Ganda	6
14	Migration and its impact on adiposity and type 2 diabetes 2007 ·Nutrition ·Anoop Misra, Om P. Ganda	200
15	Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation 2006 ·Journal of Vascular Surgery ·Gautam Shrikhande, Lalita Khaodhiar, Salvatore T. Scali, Christina Lima, (unknown), Katherine A. Dudley, Om P. Ganda, Christiane Ferran, Aristidis Veves	19
16	The role of lipid management in diabetes 2005 ·Cardiology Clinics ·Om P. Ganda	0
17	Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia 1995 ·The American Journal of Medicine ·Philip Raskin, Om P. Ganda, Sherwyn Schwartz, David A Willard, Julio Rosenstock, (unknown), Michael D. Cressman, (unknown), Bonnie H. Weiner, Mark E. McGovern, (unknown), (unknown), (unknown)	21
18	Coronary artery disease is the major determinant of excess mortality in patients with insulin-dependent diabetes mellitus and persistent proteinuria. 1992 ·Journal of the American Society of Nephrology ·James H. Warram, Lori M. Laffel, Om P. Ganda, A.Richard Christlieb	19
19	Markedly increased erythrocyte sedimentation rate, hyperfibrinogenemia, and peripheral vascular disease in diabetic patients: association with clinical implications 1988 ·The American Journal of Medicine ·Om P. Ganda	8
20	Hormone-fuel concentrations in anephric subjects. Effect of hemodialysis (with special reference to amino acids). 1976 ·Journal of Clinical Investigation ·Om P. Ganda, T. T. Aoki, J. Stuart Soeldner, R. Sean Morrison, George F. Cahill	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact